Inovio Pharmaceuticals (INO +7.3%) says early data from a Phase I study assessing its PENNVAX-G...

|About: Inovio Pharmaceuticals, Inc. (INO)|By:, SA News Editor

Inovio Pharmaceuticals (INO +7.3%) says early data from a Phase I study assessing its PENNVAX-G global HIV vaccine demonstrated "strong immune responses and safety."